Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review
- PMID: 17988791
- DOI: 10.1016/j.eururo.2007.10.013
Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review
Abstract
Objectives: This systematic literature review discusses the efficacy and safety of botulinum toxin type A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity (NDO) and urinary incontinence or overactive bladder symptoms of neurogenic origin (NOAB).
Methods: A MEDLINE and EMBASE search for clinical studies with botulinum toxin A injected into the detrusor of adults with NDO was performed. For several efficacy and safety variables data were extracted by one person and independently quality-controlled by another person. Extracted data were reviewed to propose recommendations for use in clinical practice based on level of evidence and expert opinion.
Results: A total of 18 articles evaluating the efficacy or safety of Botox in patients with NDO and incontinence/NOAB resistant to antimuscarinic therapy, with or without clean intermittent self-catheterisation (CIC), were selected. The amount of Botox injected was mostly 300 U, usually as 30 injections of 10 U/ml in the bladder (excluding the trigone) under cystoscopic guidance and with different types of anaesthesia. Most of the studies reported a significant improvement in clinical (approximately 40-80% of patients became completely dry between CICs) as well as urodynamic (in most studies mean maximum detrusor pressure was reduced to < or =40 cm H(2)O) variables and in the patients' quality of life, without major adverse events.
Conclusions: Botox injections into the detrusor provide a clinically significant improvement in adults with NDO and incontinence/NOAB refractory to antimuscarinics. It seems to be very well tolerated. However, more adequately powered, well-designed, randomised, controlled studies evaluating the optimal dose, number and location of injections, impact on antimuscarinic regimen and CIC use, duration of effect, and when to perform repeat injections are warranted.
Comment in
-
Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?Eur Urol. 2008 Feb;53(2):240-1. doi: 10.1016/j.eururo.2007.10.045. Epub 2007 Nov 1. Eur Urol. 2008. PMID: 17997019 No abstract available.
Similar articles
-
Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.J Pediatr Urol. 2009 Jun;5(3):156-64. doi: 10.1016/j.jpurol.2009.01.005. Epub 2009 Mar 4. J Pediatr Urol. 2009. PMID: 19264554
-
Efficacy and safety of botulinum toxin A intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic review.Drugs. 2013 Jul;73(10):1055-66. doi: 10.1007/s40265-013-0068-5. Drugs. 2013. PMID: 23775527
-
An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.Eur Urol. 2014 May;65(5):981-90. doi: 10.1016/j.eururo.2013.10.033. Epub 2013 Nov 1. Eur Urol. 2014. PMID: 24239446
-
Botulinum toxin injections for adults with overactive bladder syndrome.Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005493. doi: 10.1002/14651858.CD005493.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2011 Dec 07;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. PMID: 17636801 Updated.
-
Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis.Eur Urol. 2012 Nov;62(5):816-30. doi: 10.1016/j.eururo.2012.02.036. Epub 2012 Feb 25. Eur Urol. 2012. PMID: 22397851
Cited by
-
Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder.Neurourol Urodyn. 2023 Jan;42(1):366-374. doi: 10.1002/nau.25107. Epub 2022 Dec 1. Neurourol Urodyn. 2023. PMID: 36455284 Free PMC article. Clinical Trial.
-
OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.Adv Ther. 2013 Sep;30(9):819-33. doi: 10.1007/s12325-013-0054-z. Epub 2013 Sep 27. Adv Ther. 2013. PMID: 24072665 Free PMC article. Clinical Trial.
-
Autonomic Dysregulation in Multiple Sclerosis.Int J Mol Sci. 2015 Jul 24;16(8):16920-52. doi: 10.3390/ijms160816920. Int J Mol Sci. 2015. PMID: 26213927 Free PMC article. Review.
-
Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial.Int Urogynecol J. 2024 Jan;35(1):119-126. doi: 10.1007/s00192-023-05685-0. Epub 2023 Nov 22. Int Urogynecol J. 2024. PMID: 37991564 Clinical Trial.
-
Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome.Int J Environ Res Public Health. 2021 Aug 19;18(16):8743. doi: 10.3390/ijerph18168743. Int J Environ Res Public Health. 2021. PMID: 34444493 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous